NexoBrid® EscharEx® About MediWound One Pager Corporate Deck Recent Updates A New Paradigm in Treatment of Severe Burns Indication: Eschar removal in deep partial-thickness and full-thickness thermal burns Classification: Orphan biological drug Target Audience: Hospitalized patients Status: U.S./EU/Japan approved EMAFDA Read More Next-Generation Enzymatic Therapy Candidate for Wound Care Indication: Debridement of chronic/hard-to-heal wounds Classification: […]